Allogene Form 144: 2,867 shares proposed sale

Allogene Therapeutics submitted a Form 144 notice for the proposed sale of 2,867 shares of Common Stock, filed 04/01/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services.

Rhea-AI Filing Summary

Allogene Therapeutics submitted a Form 144 notice for the proposed sale of 2,867 shares of Common Stock, filed 04/01/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares reflect the vesting of a restricted stock unit award dated 03/31/2026 granted under the issuer's equity compensation plan.

Insights

Equity Compensation Analyst

Form 144 lists a small post-vesting sale notice for vested RSUs.

The filing records the vesting of 2,867 restricted stock units on 03/31/2026 and a Form 144 notice dated 04/01/2026 proposing resale via Morgan Stanley Smith Barney LLC. This is a routine transfer of vested compensation.

Cash‑flow treatment and pricing details are not provided in the excerpt; subsequent transaction filings will state actual sale amounts and proceeds.

Key Figures

Shares proposed for resale: 2,867 shares Form 144 filing date: 04/01/2026 RSU vesting date: 03/31/2026

3 metrics

Shares proposed for resale 2,867 shares Securities to be sold / vesting event dated 03/31/2026

Form 144 filing date 04/01/2026 Date listed alongside CUSIP and broker in the notice

RSU vesting date 03/31/2026 Vesting of restricted stock unit award granted under issuer equity plan

Key Terms

restricted stock unit, Form 144, vesting

3 terms

restricted stock unit financial

"Vesting of restricted stock unit award"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

vesting financial

"03/31/2026 | Vesting of restricted stock unit award"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Allogene (ALLO) Form 144 notice mean?

A Form 144 notice indicates a proposed sale of restricted or control securities by an affiliate. This filing shows a proposed sale of 2,867 shares associated with vested RSUs, filed on 04/01/2026 through Morgan Stanley Smith Barney.

Were the Allogene shares newly vested or sold already?

The shares were reported as vested on 03/31/2026 as restricted stock units. The Form 144 dated 04/01/2026 notices a proposed resale; the excerpt does not confirm whether the shares have been sold yet.

Who is handling the sale in the Allogene Form 144?

The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services at 1 New York Plaza as the broker/agent. The excerpt names the broker but does not show execution details or sale proceeds.

Does the Form 144 disclose proceeds or sale price for ALLO shares?

The provided excerpt does not state sale proceeds or per‑share price. It shows the quantity (2,867 shares) and filing date (04/01/2026). Execution and pricing appear in subsequent transaction reports, not in this notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 07:13 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002057918
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Allogene Therapeutics, Inc.
SEC File Number	001-38693
Address of Issuer	210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	(650) 457-2700
Name of Person for Whose Account the Securities are To Be Sold	Beneski Benjamin Machinas
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2867	7167.50	243777920	04/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/31/2026	Vesting of restricted stock unit award	Allogene Therapeutics, Inc.			2867	03/31/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	04/01/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	BENJAMIN MACHINAS BENESKI
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)